A Study of CT-388 in Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus
Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2026-11-30
Target enrollment:
Participant gender:
Summary
This is a multi-center, randomized, double-blind, placebo-controlled, parallel group dose-finding study to evaluate the efficacy and safety of CT-388 at low, middle, and high doses in participants who are overweight or obese with Type 2 diabetes mellitus (T2DM).